Overview
Intellia is a pioneer in the development of CRISPR/Cas9 genome editing and is rapidly moving experimental therapies towards the clinic.
Our company’s unique strengths include our modular lipid nanoparticle delivery system and our determined focus on product development.
Programs & Pipeline
Each one of us together for patients
We believe our modular approach to selecting our in vivo and ex vivo programs positions us to build a full-spectrum genome editing company, with a pipeline across a range of indications. This approach enables us to generate a wealth of data that opens the potential therapeutic applications of the CRISPR/Cas9 technology across a broad range of diseases.
Full-Spectrum Blog
From July 5 – July 9, Intellia will be closed for our annual summer shutdown. This is just one of the many great employee benefits that we offer! Check out our other benefits here: https://t.co/fpNp8aEgxC #IamIntellia #CRISPR #genomeediting https://t.co/EpNHKMe77j
From all of us at Intellia, we wish you a safe, healthy and fun #IndependenceDay! #FourthofJuly https://t.co/Ot87KA4ojC